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Abstract: In this report we review our results on the development of 1,2-annulated adamantane heterocyclic derivatives and we discuss the 
structure-activity relationships obtained from their biological evaluation against influenza A virus. We have designed and synthesized numerous 
potent 1,2-annulated adamantane analogues of amantadine and rimantadine against influenza A targeting M2 protein the last 20 years. For their 
synthesis we utilized the key intermediates 2-(2-oxoadamantan-1-yl)acetic acid and 3-(2-oxoadamantan-1-yl)propanoic acid, which were obtained 
by a simple, fast and efficient synthetic protocol. The latter involved the treatment of protoadamantanone with different electrophiles and a carbon-
skeleton rearrangement. These ketoesters offered a new pathway to the synthesis of 1,2-disubstituted adamantanes, which constitute starting 
materials for many molecules with pharmacological potential, such as the 1,2-annulated adamantane heterocyclic derivatives. To obtain additional 
insight for their binding to M2 protein three structurally similar 1,2-annulated adamantane piperidines, differing in nitrogen position, were studied 
using molecular dynamics (MD) simulations in palmitoyl-oleoyl-phosphatidyl-choline (POPC) hydrated bilayers. 
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NFLUENZA is an acute viral infection of the upper and 
lower respiratory tract, characterized by sudden onset 
of fever, cough, myalgia, malaise and other symptoms. 
Because of its extremely high transmissibility, influenza 
affects annually a large part of the world's population. In-
fections range from mild to severe, while pneumonia is the 
most common serious complication. Underlying conditions 
such as lung diseases, auto-immune, neurological or cardi-
ovascular disorders, immunosuppressive therapy, diabetes 
and pregnancy are predisposing factors for hospitaliza-
tion.[1] Seasonal influenza viruses that cause influenza in 
vertebrates (including birds, humans, and other mammals) 
are divided into types A, B, C and D,[2] and represent four of 
the seven genera of the Orthomyxoviridae family. The clas-
sification of the type of the virus is based on the antigenic 
specificity of the internal nucleoprotein (NP) and matrix (M) 
proteins.[3] Influenza D viruses primarily affect cattle and 
are not known to infect or cause illness in people.[2] The 
clinical aspects and epidemiology of influenza C virus infec-
tions are poorly characterized and rely mainly on a few 
studies in paediatric populations.[4] On the other hand, 
influenza A and B viruses circulate and affect each year 
approximately 5–10 % of the adult and 20–30 % of the pae-
diatric population,[5] causing seasonal epidemics of disease 
with significant morbidity and mortality, particularly in high 
risk groups. Worldwide, annual influenza epidemics are 
estimated to result in about 3 to 5 million cases of severe 
illness, and about 290.000 to 650.000 respiratory deaths.[2] 
Although pandemics appear irregularly, there is always a 
permanent risk of a sudden influenza pandemic, such as the 
‘Spanish flu’ in 1918,[6] the most deadly pandemic in the his-
tory of mankind, and the swine-origin H1N1 pandemic in 
2009. Only influenza type A viruses are known to have 
caused pandemics.[7] 
Influenza A Virus 
As members of the Orthomyxoviridae family, influenza A 
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negative-oriented single-stranded RNA genome. The virus 
particles are pleomorphic, forming usually roughly spheroi-
dal virions with a diameter of approximately 100 nm, as 
well as elongated filamentous viral particles reaching over 
300 nm in length.[8] Despite their pleomorphism, the viral 
particles comprise three basic structural characteristics; 
the envelope, the matrix protein (M1) and the virion core 
(Figure 1). The viral envelope is a lipid bilayer derived from 
the plasma membrane of the infected cell. The envelope 
contains three transmembrane proteins; hemagglutinin 
(HA), neuraminidase (NA) and the M2 ion channel.[9] HA 
and NA proteins are anchored in the lipid raft domain of the 
viral envelope, projecting away from the viral surface, and 
are the two main antigenic determinants of the virus. IAVs 
are further classified into subtypes depending on the 
genetic and antigenic properties of the hemagglutinin (HA) 
and neuraminidase (NA) surface glycoproteins and their 
combinations. To date, 18 different HA subtypes and 11 dif-
ferent NA subtypes are known to exist in nature.[3] Changes 
in the hemagglutinin and neuraminidase surface antigens 
are responsible for the appearance of antigenically novel 
strains that evade host immunity and cause reinfections. 
 Hemagglutinin is a homotrimeric glycoprotein and is 
the major envelope protein (∼ 80 %). HA has a multifunc-
tional activity as both an attachment factor and membrane 
fusion protein, thus mediating virus entry and infectivity.[9] 
NA is the second most abundant (∼ 17 %) envelope protein 
and forms tetrameric spikes in the surface of the viral 
envelope. Being responsible for the release of newly 
formed virions from infected cells, by enzymatically cleav-
ing the sialic acid groups from host glycoproteins, NA is 
required for influenza virus replication.[9] The third protein 
of the viral envelope, M2 ion channel, functions as a homo-
tetramer, forming a proton-selective ion channel in the 
centre of four helices.[10] On average, there are ∼ 16–20 ion 
channels in every virion,[9] nevertheless, M2 is a multifunc-
tional protein with roles in virus entry, assembly and 
budding. The envelope and its three integral membrane 
proteins HA, NA, and M2 overlay a matrix of M1 protein, 
which is essential for viral integrity and encloses the virion 
core. 
 Internal to the M1 matrix, in the viral core, are found 
the nuclear export protein (NEP; also called nonstructural 
protein 2, NS2) and the helical viral ribonucleoprotein 
(vRNP) complexes. vRNPs comprise the eight viral RNA 
(vRNA) segments (PB2, PB1, PA, HA, NP, NA, M and NS 
genes)[12] encoding for the viral proteins. Each one of the 
vRNPs is bound to multiple copies of viral nucleoprotein 
(NP) and carries its own single, heterotrimeric RNA-
dependent RNA polymerase complex (3P complex), 
composed of two “polymerase basic” (PB1, PB2) and one 
“polymerase acidic” (PA) subunits.[8,9] 
The Influenza Virus Replication Cycle 
IAV predominantly enters cells by endocytosis. The virion is 
internalized in an endosome and its acidification allows 
vRNPs to being released and transferred into the nucleus, 
where they serve as template for genome transcription and 
replication. Progeny vRNPs are then exported to the cyto-
plasm and finally trafficked to the plasma membrane for 
incorporation into newly forming virions. M2 and NA are 
the major proteins that mediate release of the virions from 
infected cells. M2 promotes scission of budding viruses 
from the plasma membrane, whereas NA prevents virus 
aggregation at the cell surface.[13] Therefore, there is an 
utmost need for new M2 inhibitors as antivirals. 
Prevention and Treatment of Influenza 
Virus Infections 
The usage of the first class of commercially anti-influenza 
drugs, amantadine and rimantadine (M2 proton channel 
blockers) has been discontinued. Since 2005, the aman-
tadine-insensitive Ser-to-Asn mutation at position 31 in M2 
(S31N) has become globally prevalent, abrogating the clini-
cal usefulness of amantadine and possibly other previously 
reported M2 inhibitors due to the loss of the V27 pocket for 
the adamantyl cage.[14,15] The currently licensed antiviral 
agents for the prevention and treatment of influenza A 
infections are the neuraminidase inhibitors (NAIs) and the 
polymerase inhibitors (Figure 2). The NAIs mimic the tran-
sition-state analogue of the natural substrate of the NA 
enzyme, thereby blocking NA cleavage activity. Zanamivir 
and oseltamivir are the only two NAIs approved in most 
countries. Newer NAIs include laninamivir, approved in 
Japan, and peramivir, approved in Japan, China, South 
Korea, and the USA.[16] Finally, favipiravir (PB1 inhibitor), 
pimodivir (PB2 inhibitor), and baloxavir marboxil (PA inhib-
itor), that target different protein subunits of the influenza 
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polymerase complex are in advanced clinical development, 
with baloxavir being already approved in both the USA and 
Japan. All of the polymerase inhibitors show synergistic 
interactions with NAIs in preclinical models, and are orally 
administered.[17] 
 The most effective way to prevent morbidity and 
mortality caused by severe influenza infections is generally 
considered to be vaccination. However, the existing 
influenza vaccines fail to provide a broadly protective and 
long-lasting immunity and require annual updating, 
therefore the administration of antiviral drugs is an 
important first line of defense against the virus. 
 In this review we provide an overview of 1,2-
annulated adamantane heterocyclic derivatives, synthes-
ized by our group, which were evaluated as anti-influenza 
A agents and are thought to inhibit the M2 ion channel 
because of their structural similarities with the M2 proton 
channel blockers amantadine and rimantadine. 
Influenza A M2 Channel – Mechanism of 
Action of Amantadine-Based Drugs 
The M2 protein of the influenza A virus (A/M2) forms a 
homotetrameric acid-activated proton selective channel 
that is essential for several different functions during the 
life cycle of the virus.[18–23] When the virus enters the 
infected cell by endocytosis, the influenza A M2 channel is 
activated in response to the lowered pH of the endosome, 
resulting in proton flux into the virus interior, which triggers 
the dissociation of the viral RNA from matrix M1 protein 
and the fusion of the viral and endosomal membranes. 
After these events the viral RNA is released to the cyto-
plasm and replicated by the host cell.[19,24,25] In later stage 
of virus replication, the M2 protein maintains the high pH 
of the trans-Golgi network and prevents premature confor-
mational changes of hemagglutinin in viruses with a high 
pH optimum of hemagglutinin-induced fusion.[26] 
 The M2 protein of the influenza A virus is a 97-resi-
due single-pass membrane protein, containing a short N-
terminal periplasmic domain, a transmembrane (TM) 
domain, and a C-terminal cytoplasmic tail.[27] Ami-
noadamantane (Aamt) class of antiviral drugs such as, 
amantadine (Amt) and rimantadine (Rim), have the M2 pro-
ton channel of the wild type (WT) influenza A as their pri-
mary target by blocking proton conductance through the 
transmembrane domain of M2 (M2TM).[28]  
 N-terminal domain is a highly conserved residue 
sequence and assists M2 incorporation into the virion,[29] 
however the C-terminal domain of the protein interacts 
with the matrix M1 protein which is necessary for virus 
packaging and budding.[30] Besides these two regions there 
is a transmembrane domain (TM, residues 23-46) compris-
ing the pore of a proton channel with a tilt of about 25o and 
an amphipathic helix (AH, residues 47-62) and are essential 
for the functional integrity of the channel inducing the 
membrane curvature and membrane scission.[31] The 
M2TM is the minimal construct needed for tetramerization, 
selective proton transport and Amt binding, since the rate of 
conductance of the M2TM domain and the inhibition by the 
Amt correspond to those of the full-length protein.[14,32–35] 
M2TM domain accomodates the proton-conducting 
 
 





214 V. PARDALI et al.: 1,2-Αnnulated Adamantane Heterocyclic Derivatives … 
 




residue, histidine 37 (His37),[36] and the channel-gating res-
idue, tryptophan 41 (Trp41).[37] The open state of the chan-
nel is a result of the low pH in the viral endosome, when the 
imidazole rings of the four His37 residues are protonated 
causing destabilization of helix-helix packing by electro-
static repulsion. The His tetrad is located near the center of 
the channel acting as a pH sensor and controls the activa-
tion of the channel at pH lower than 6.0, leading ultimately 
to the unpacking of the influenza viral genome and to path-
ogenesis.[38] A secondary role for His37 is to serve as a shut-
tle that is sequentially protonated and deprotonated as an 
excess proton transits the activated channel. The side 
chains of Trp41 under basic conditions alter their confor-
mation closing the C-terminal pore below His37 and form a 
gate that prevents proton flow through the pore.[35] The 
Trp41 tetrad, next to the His37 tetrad toward the C-termi-
nus and virus interior, comprises a pH-dependent gate for 
proton conductance.[37] The cooperativity between the 
protonation state of the His37 tetrad, conformations of the 
protein backbone and Trp41 side chains is crucial for the pH 
dependent activation mechanism of the channel.[39–41] In 
alkaline conditions the imidazole rings of the His37 residues 
at Nδ1 are deprotonated[42] and the Trp41 side chains close 
the C-terminal pore below His37, effectively blocking pro-
ton flow though the channel. Inside the pore, ordered 
waters form continuous hydrogen-bonding networks that 
span the pore from the Val27 tetrad to His37.[43,44] 
 The binding site of Amt and Rim is the lumen of the 
four-helix bundle of the M2TM interacting with the pore-
lining residues Val27, Ala30, Ser31 and Gly34 of the N-
terminus portion of the M2TM.[45] The hydrophobic 
adamantane moiety of Amt or Rim is positioned in N-
terminus on the exterior of the virus with the ammonium 
group directed downwards toward His37. The adamantane 
is located within a predominantly hydrophobic pocket 
formed by the side chains of Val27, Ala30 and Ser31. The 
hydroxyl of Ser31 forms an internal hydrogen bond to a 
main-chain carbonyl of Val27, increasing the effective 
hydrophobicity of the environment.[46] The ammonium 
group of the Aamt is stabilized due to proximal positioned 
waters comprising the Ala30 layer, followed by the Gly34 
water layer. Placement of the drug within the pore disturbs 
the overall fourfold rotational symmetry, of the largely 
symmetrical M2 pore and its water network. The 
alkylammonium groups of Amt and Rim form three 
hydrogen bonds with water donating protons, making it 
impossible to form interactions with each of the four Ala30 
waters maintaining the symmetry. Thus, Aamts are slightly 
tilted inside the binding site, with the ammonium group 
displaced away from the central axis and toward part of the 
Ala30 waters.[46] 
Adamantane as a Versatile Building 
Block 
Generally polycyclic cage scaffolds hold a prominent place 
in medicinal chemistry, and they have been successfully 
used in drug design strategies. These cage moieties, 
including the adamantane ring can serve either as starting 
frameworks for the development of novel therapeutic 
agents or they can be incorporated into existing drugs to 
improve their pharmacokinetic and pharmacodynamic 
properties.[47,48] 
 In particular, adamantane is a rigid, almost 
unstrained structure of high symmetry and unique 
geometry. Due to its intrinsic lipophilic characteristics, it 
enhances the permeability of the compounds through cell 
membranes and facilitates the blood-brain barrier 
penetration. It also modulates the orientation and the 
binding to a hydrophobic pocket of the target in order to 
increase selectivity. Furthermore, its bulkiness and rigidity 
reduce the metabolic cleavage, thus extending the activity 
and the half-time of a drug.[48,49] Because of all the 
aforementioned, the privileged nature of the adamantane 
framework indicates that it constitutes a versatile building 
block in order to increase the drug-like properties of 
compounds.[50,51] Since many years, the adamantane 
moiety has yielded a plethora of compounds which display 
activity as antivirals, chemotherapeutic agents, sedatives, 
antihyperglycemic agents and neurotherapeutics.[52–56] 
 The functionalization of this scaffold is achieved by 
halogenation in the bridgehead positions through an easy 
activation of the C-H bond of the tertiary carbon atoms, 
giving rise to a large number of synthetic analogues with 
desired properties.[57] 
 Five drugs that feature an adamantane component 
are currently in clinical use (Figure 3) and many more are 
 
Figure 3. Currently available adamantane derivatives in 
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under development. The approved therapeutic compounds 
are memantine, tromantadine, adapalene, vildagliptin and 
saxagliptin, and they are used to a broad spectrum of 
indications such as viral infections (Herpes simplex), 
neurodegenerative disorders (Parkinson’s disease, 




The first class of influenza antivirals was aminoadamantane 
derivatives that revolutionized the drug market (Figure 2). 
As previously described, the aminoadamantanes, 
amantadine and rimantadine, block the ion channel formed 
by the M2 protein of influenza A virus. All known M2 
channel inhibitors are endowed with a hydrophobic 
scaffold, mostly an adamantane ring attached by a polar 
headgroup, frequently a primary or secondary amine.[57]  
 We, and other research groups,[59] investigated the 
potential of aminoadamantanyl-containing analogues as 
anti-influenza agents. Accordingly, we modified the 
headgroup to obtain M2 inhibitors with improved potency 
profile and explore new chemistry. To start with, we 
synthesized N-substituted analogues of rimantadine’s 2-
isomer,[60] which were more potent than rimantadine 
against influenza virus A strain H2N2. Encouraged by these 
preliminary results, our next approach was to attach a spiro 
amino substituted cycloalkane to the position 2 of the 
adamantane backbone, resulting in spirocyclobutane and 
spirocyclopentane congeners of 2-rimantadine.[60] Then, 
we examined the incorporation of the amino group into an 
heterocyclic ring and we synthesized three-, four-, and five-
membered heterocycles integrated into the structure of 1-
rimantadine.[61] The pyrrolidine and the azetidine 
counterparts exhibited activity in the order of 1.9 μM 
against two different influenza A strains.[61] Moreover, we 
introduced a spiro connection between the heterocyclic 
ring and the adamantane moiety[62] and the obtained spiro 
heterocyclic adamantane derivatives were active with EC50s 
in the submicromolar range. 
 We will also review here the design, synthesis and 
pharmacological evaluation of 1,2-annulated adamantane 
heterocyclic analogues[63–65] aiming at rigidifying the 
conformation of the compounds to avoid binding entropic 
penalty and explore certain ligand binding orientations 
inside the M2 pore. This series of compounds (Figure 4) 
comprises the unsubstituted adamantanopyrrolidines 19 
and 27[63] and adamantanopiperidines 45, 60 and 67.[64] To 
explore the role of the amine nitrogen atom substitution in 
the anti-influenza A activity, the N-methyl and N-ethyl 
analogues 20, 21, 29, 47, 62, 63 and 69 were also 
synthesized.[63,64] Moreover, we introduced a second amino 
functionality or an oxygen atom, resulting in compounds 
31, 33, 34,[63] 50, 51 and 52.[64] We also tested for their 
antiviral activity the highly functionalized precursors γ- and 




Ketoesters and ketoacids of adamantane series are key 
structures for the preparation of various adamantane 
analogues including the 1,2 annulated adamantane 
 
 




216 V. PARDALI et al.: 1,2-Αnnulated Adamantane Heterocyclic Derivatives … 
 




derivatives.[66] In general, protoadamantanone 1 consti-
tutes basic intermediate for the 1,2-disubstituted adaman-
tanes and it was used as starting compound for the 
formation of the adamantanecarboxylic acids 7 and 12.[67] 
Majerski’s group had described the synthesis of 
protoadamantanone from the commercially available  
1-adamantanol since 1979.[68] 1-Adamantanol was treated 
with lead tetraacetate and iodine in benzene and the 
resulting iodo ketone was refluxed with potassium hydrox-
ide to afford the target compound 1 in excellent yields 
(Scheme 1).[68] Heating of the mixture composed of 1-ada-
mantanol, lead tetraacetate and iodine for 2 h at 75–76 °C 
improved the reaction yield and decreased the amount of 
the unreacted starting compound.[67] 
 As depicted in Scheme 2, protoadamantanone 1 was 
subjected to Reformatsky reaction with bromoacetic acid 
ethyl ester in the presence of zinc metal. Upon saponifica-
tion, the hydroxyacid 2 was afforded in low yields along with 
some starting ketone. In an effort to obtain the derivative 2 
in higher yields, protoadamantanone 1 was treated with 
LiCH2COOCH3, which was prepared by lithium bis(tri-
methylsilyl)amide and methyl ethanoate in one pot,  
and upon hydrolysis of the intermediate ester 3 under  
basic conditions, the desired compound 2 was yielded 
quantitatively. The hydroxyacid 2 was heated with formic 
acid and gave a mixture of the respective ester 4 as a major 
product and the lactone 5 in traces. Subsequent 
saponification of the mixture and Jones oxidation of the 
intermediate compound 6 led to the desired ketoacid 7.[67]  
 For the preparation of the ketoacid 12 (Scheme 3), 
the acetylenic diol 8 was formed by a typical Grignard reac-
tion between protoadamantanone 1 and the dimagnesium 
derivative of propargylic alcohol. Catalytic hydrogenation 
with platinum (IV) oxide afforded the respective saturated 
diol 9 which was subsequently heated with formic acid to 
provide the corresponding diester 10. Employment of the 
previously described methodology, saponification to afford 
the diol 11 and oxidation with Jones reagent gave the 
desired ketoacid 12 quantitatively.[67] 
1,2-Annulated Adamantanopyrrolidines 
As illustrated in Scheme 4, 2-oxo-1-adamantanacetic acid 7, 
the synthesis of which has been described above (Scheme 
2),[67] was the key structure to afford the 1,2-annulated 
adamantanopyrrolidines 19, 20 and 21.[63,65] The ketoacid 7 
was esterified with ethanol in the presence of thionyl chlo-
ride to give the ketoester 13. The latter was converted to 
the respective oxime ester 14 upon reaction with hydroxyl-
amine hydrochloride and sodium acetate. Compound 14 
was hydrogenated for 10 h at 120 ◦C using a Raney nickel 
catalyst to provide the lactam 15 along with the N-ethyl 
lactam 16 in different yields. Under different hydrogena-
tion reaction conditions, either a mixture of the lactam 16 
and the amino ester 17 or the N-methyl lactam 18 was 
afforded. The amino ester 17 was refluxed in xylenes and 
the analogue 15 was exclusively formed. γ-lactams 15, 16 
and 18 were reduced to the cyclic amines 19, 21 and 20 
respectively by using lithium aluminum hydride. The N-
methyl adamantanopyrrolidine 20 was also prepared upon 
N-acylation of the respective unsubstituted congener 19 
with ethyl chloroformate and subsequent reduction of the 
formed carbamate 22.[63,65] 
 
 




Scheme 2. Synthetic route to the 2-oxo-1-adamantanacetic 
acid building block 7.[67] 
 
 
Scheme 3. Synthetic route to the 2-oxo-1-adamantane-
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Scheme 4. Synthesis of the 1,2-annulated adamantanopyrrolidines 19, 20 and 21.[63,65] 
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 The synthetic routes for the annulated derivatives 
27, 29, 31, 33 and 34 are depicted in Scheme 5.[63] Esterifi-
cation of the 2-oxo-1-adamantane carboxylic acid 23 led 
to ethyl ester 24. Reductive cyanation of the resulting 
ester 24 was the key step for the synthesis of the lactams 
26 and 28, which are the precursors of the target 
compounds 27 and 29 respectively. The use of toluene-
sulphonylmethyl isocyanide (TOSMIC) as nucleophile 
provided the cyanoester 25 in good yields. Hydrogenation 
of the latter by using two different sets of reaction 
conditions afforded the γ-lactams 26 and 28 which were 
then reduced to the desired pyrrolidine 27 and its N-ethyl 
counterpart 29 respectively.[63,65] 
 The ketoester 24 was coupled with hydroxylamine 
hydrochloride in the presence of sodium acetate, and a 
mixture of the oxime 30 and the oxazolone 31 was isolated. 
Then, the mixture was saponified and the acid oxime 32 
was yielded almost quantitatively. Compound 32 was sub-
limed to obtain the isoxazolone 31 exclusively.[63]  
 The pyrazolone 33 was afforded by a two-step syn-
thetic procedure of the ketoacid 23 with hydrazine and sub-
sequent sublimation of the intermediate 32. Thiation of the 
pyrazolone 33 with Lawesson’s reagent, generated the cor-
responding pyrazolothione 34.[63] 
Synthesis of 1,2-Annulated Adamantane 
Cycloalkanamines 
An example is given for compound 42.[63] For its synthesis 
(Scheme 6), the tetrahydrofuranic derivative 35 firstly 
reacted with the triphenyldibromophosphorane which was 
prepared in situ by addition of Br2 to a solution of 
triphenylphosphine. The resulting dibromide analogue 36 
was treated with sodium cyanide in DMSO to obtain a 
mixture of bromonitrile 37 and dinitrile 38. The mixture was 
further heated in the presence of sodium cyanide in the 
same solvent to afford the analogue 38 in excellent yields. 
By employment of the Thorpe-Ziegler reaction, dinitrile 38 
underwent an intramolecular condensation catalyzed by 
LDA to form the enamine 39. Subsequent acid-promoted 
hydrolysis of the latter gave rise to the racemic cyclic 
ketone 40, which was converted to the respective oxime 41 
upon treatment with hydroxylamine as previously 
described. Compound 41 was hydrogenated over Raney 
nickel to provide the desired cyclopentanamine 42.[63] 
 
 
Scheme 6. Synthetic procedure for the preparation of the 1,2-annulated adamantane cyclopentanamine 42.[63] 
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Synthesis of 1,2-Annulated 
Adamantanopiperidines 
The formation of the piperidines 45 and 47[64] (Scheme 7) 
was achieved following a synthetic procedure similar to 
that of the pyrrolidines 19 and 20 (Scheme 4). Starting from 
2-oxo-1-adamantanepropionic acid 12, the oxime 43  
was afforded almost quantitatively by refluxing an ethan-
olic solution of the ketoacid 12 with hydroxylamine 
hydrochloride and sodium acetate. Compound 43 was 
subjected to catalytic hydrogenolysis using a Raney nickel 
catalyst to yield the lactam 44 which was reduced to the 
respective piperidine 45 using lithium aluminum hydride. 
The latter was N-acylated with ethyl chloroformate in the 
presence of triethylamine and the carbamate protected 
amine 46 was reduced to the N-methyl amine 47 with 
LiAlH4.[64,65] 
 Piperidines 60, 62 and 63[64] were prepared as out-
lined in Scheme 8. Protoadamantanone 1 reacted with di-
methylsulfonium methylide to form the epoxide 48 as a 
mixture of endo/exo epimers in a 1 : 15 ratio. Oxirane ring 
opening under acidic conditions provided the adamantane 
diol 49. Intramolecular cyclization of 49 gave the dioxane 
50 in poor yields, upon heating with formaldehyde in con-
centrated sulfuric acid. The diol 49 was treated with thionyl 
chloride and afforded a reaction mixture of the dioxathiane 
51 and the oxetane 52. Compounds 51 and 52 were isolated 
separately after chromatographic purification. As it seems, 
the temperature may have a key role in the formation ratio 
of the two products. Traces of the cyclic sulfite 51 were 
detected at 43 ◦C. Treatment of the cyclic ether 52 with 
hydrobromic acid afforded the bromoalcohol 53. The ox-
etane 52 was converted to the dibromide 54 as previously 
 
 
Scheme 8. Synthetic procedures for the preparation of the 1,2-annulated adamantanopiperidines 60, 62 and 63,[64,65] and the 
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described using the freshly prepared triphenyldibromo-
phosphorane in one pot procedure.[69] The adamantane 
halide 54 was heated with sodium cyanide at high temper-
ature to provide the dinitrile 55. The latter was mixed with 
a saturated ethanolic solution of gaseous HCl and was left 
on standing for a long period of time. Mild acidic hydrolysis 
of the obtained imino ether hydrochloride 56 gave the 
cyanoester 57 which was hydrogenated using Raney nickel 
catalyst. The hydrogenolysis products were a mixture of the 
δ-lactams 58 and 59. By employing the abovementioned 
procedure for the synthesis of piperidines 45 and 47, reduc-
tion of the compounds 58 and 59 afforded the adamanta-
nopiperidi-nes 60 and 63, whereas N-acylation and sub-
sequent LiAlH4 catalyzed reduction of the intermediate 61 
led to the N-methyl piperidine 62.[64,65] 
 The procedure applied for the synthesis of the cyclic 
amines 67 and 69[64] is illustrated in Scheme 9. Formation of 
the nitrile 65 was based on the nucleophilic addition of a 
phosphonate-stabilized carbanion onto the ketoester 64 via 
a typical Horner-Wadsworth-Emmons reaction. Compound 
64 was treated with diethyl cyanomethylphosphonate, 
where sodium hydride was used as a base to deprotonate the 
latter. The olefin 65 was appeared as a mixture of E/Z stere-
oisomers with excellent E-selectivity. Catalytic hydrogenoly-
sis of the mixture and subsequent intramolecular cyclization 
provided the annulated piperidinone 66. Conversion of the 
lactam 66 to the piperidine 67 was effected by reduction with 
LiAlH4. Alkylation of the amine nitrogen atom was performed 
by C-N bond formation, firstly through N-acylation of com-
pound 67, followed by reduction of the intermediate 68 to 
afford the desired analogue 69.[64,65] 
 
EXPERIMENTAL 
Molecular Docking Calculations 
The M2TMWT-Amt crystal structure (PDB ID 2KQT) was used 
as a starting point and the Aamt ligands were docked using 
Glide (Maestro 10.3, Schrodinger, Cambridge, MA).[70] Prior 
to the docking calculations the 1,2-annulated adamantane 
piperidines 45, 60 and 67 in their ammonium form were 
built by means of Maetro 10.3, prepared using the LigPrep 
workflow and minimized by MacroModel workflow as im-
plemented on Maestro 10.3. N- and C-termini of the M2TM 
model systems were capped by acetyl and methylamino 
groups after applying the protein preparation module of 
Maestro 10.3. The structures of the protein and Aamts 
derivatives 45, 60, 67 were saved separately and were used 
for the subsequent docking calculations. The ligands were 
minimized using OPLS2005 force field, the polak-ribier con-
jugate gradient (PRCG) method and by applying a distance-
dependent dielectric constant of 4.0 until a convergence 
value of 0.001 kJ Å–1 mol–1 was reached. Docking poses of 
M2TMWT-Aamt complexes were generated by docking the 
prepared compound structures into the pore binding site of 
the M2TM. Docking was performed with Glide XP using 
GlideScore multi-ligand scoring function and carried out on 
the energy-minimized poses. Docking poses for each ligand 
were virtualy inspected using Maestro workflow and the 
pose with the best score was used in MD simulations. 
Molecular Dynamics Simulations 
The M2TMWT complexes were simulated using the experi-
mental structure of M2TM from Cady et al. (PDB ID 
2KQT),[71] which was determined at pH 7.5 in presence of 
Amt,[71,72] as initial configuration. Each M2TMWT – Aamt 
complex was embedded in a hydrated membrane of POPC 
molecules, with the 1,2-annulated adamantane piperidine 
ligand in its ammonium form. The all-atom MD simulations 
were performed with Desmond (Schrodinger, Cambridge, 
MA).[46,73,74] The POPC lipid bilayer extended 20 Å beyond 
the solutes in x,y axes, resulting in a system including 120 
lipid molecules. The bilayer was solvated using a 20 Å thick 
layer of TIP3P waters. The systems were neutralized by 
adding Na+ and Cl- ions in the water phase and to represent 
the experimental salt concentration of 0.150 M NaCl. The 
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total number of system’s atoms reached approximately 
50000. Membrane creation and system solvation were con-
ducted with the “System Builder” utility of Desmond.[73,74] 
Protein-ligand interactions were modelled using 
OPLS2005.[75–77] The TIP3P[78] model was used for water. 
Calculation of long-range electrostatic interactions, was uti-
lized by the particle mesh Ewald method,[79,80] with a grid 
spacing of 0.8 Å. Van der Waals and short-range electro-
static interactions were smoothly truncated at 9.0 Å. A con-
stant temperature was maintained in all simulations using 
Nosé-Hoover thermostat, and the Martyna-Tobias-Klein 
method was employed to control the pressure.[81] Periodic 
boundary conditions were applied (70 × 70 × 86) Å3. Multi-
step RESPA integrator[82] was used to integrate the equa-
tions of motion with an inner time step of 2 fs for bonded 
interactions and non-bonded interactions within a cut-off 
of 9 Å. An outer time step of 6.0 fs was used for non-bonded 
interactions beyond the cut-off. The equilibration protocol 
consists of a series of restrained minimizations and MD sim-
ulations designed to relax the system, while not deviating 
substantially from the initial coordinates. Initially, two 
rounds of steepest descent minimization with a maximum 
of 2000 steps and harmonic restraints of 50 kcal mol–1 Å–2 
were applied on all solute atoms, followed by 10000 steps 
of minimization without restraints. The first simulation was 
run for 200 ps at a temperature of 10 K in the NVT ensemble 
with solute heavy atoms restrained with a force constant of 
50 kcal mol–1 Å–2. The temperature was then raised during 
a 200 ps MD simulation to 310 K in the NVT ensemble with 
the force constant retained. The temperature of 310 K was 
used in the MD simulations in order to ensure that the 
membrane state is above the melting temperature state of 
271 K for POPC lipids.[83] The heating was followed by equi-
libration runs. Three stages of NPT equilibration (1 Atmos-
phere) with restraints were performed, first with the heavy 
atoms of the system restrained for 1 ns, then with solvent 
and lipid molecules restrained harmonically with a force 
constant of 10 kcal mol–1 Å–2 for 10 ns. Finally, the third 
stage, with the Cα atoms of M2TM harmonically restrained 
with a force constant of 2 kcal mol–1 Å–2 for 1 ns. The above-
mentioned was followed by a 200 ns NPT simulation with-
out restraints. Within this time, the total energy, system di-
mensions, and the RMSD reached a plateau, and the 
systems were considered equilibrated. For structural 
analyses, snapshots of the different systems were created 
with VMD[84] or Maestro.[85] Trajectories were analyzed 
with Maestro, Gromacs,[86,87] and VMD. Measurements 
were done with Gromacs tools. For the calculation of 
hydrogen bonds, a cut-off angle of 30o of deviation from 
180o between the donor-hydrogen-acceptor atoms and a 
cut-off distance of 3.5 Å between the donor and acceptor 
atoms were applied. 
 
RESULTS AND DISCUSSION 
The antiviral effects of the synthesized 1,2 annulated 
adamantane analogues 19, 20, 21, 27, 29, 31, 33, 34, 42, 45, 
47, 50, 51, 52, 60, 62, 63, 67 and 69 were determined in 
vitro against influenza A/Hong Kong/7/87 (H3N2) 
strain[63,64,69] and were compared to the activity of aman-
tadine, rimantadine and ribavirin (Table 1). 
 The adamantane heterocycles 19, 20, 21, 27, 29, 42, 
45, 47, and 67 were significantly active against influenza A 
virus, with EC50s ranging from 0.46 to 7.70 μM. Pyrrolidine 
27 and piperidine 67 were the most potent analogues  
with submicromolar EC50 values (0.46 μM and 0.6 μM, 
respectively). Compound 19 exhibited EC50 = 2.20 μM and 
its efficacy was comparable to that of amantadine. 
Incorporation of an alkyl substituent onto the nitrogen 
atom of the adamantanopyrrolidine 19 progressively 
decreased the activity of the compounds. Thus, the N-
methyl and N-ethyl counterparts 20 and 21 were found to 
be 1.5 and 3.5-fold less potent than their parent compound 
19, respectively (EC50 20 = 3.40 μM and EC50 21 = 7.70 μM). 
It is noteworthy that shifting the nitrogen atom from 
position 3 to the C-4 position of the aminoadamantane 
heterocycle 19 increased the activity with the EC50 value of 
27 being 5-fold lower (EC50 27 = 0.46 μM). Compound 27 
was 4-fold more potent compared to amantadine, almost 
equipotent to rimantadine and 19-fold more effective than 
ribavirin. A similar trend was observed for the N-alkylated 
analogue 29 (EC50  29 = 2.40 μΜ), which was 3-fold more 
active than the N-ethyl congener 21 (EC50 21 = 7.70 μΜ). 
Taking a closer look at the effect of the size of the N-
heterocyclic ring, replacement of the pyrrolidine ring in 19 
with the piperidine moiety in 45 lowered the activity by 2-
fold (EC50 45 = 4.1 μΜ), compared to derivatives 19 and 20 
respectively. In the context of alkylation, the N-methylated 
analogue 47 exhibited potency similar (in the order of 4 
μM) to the corresponding NH compound 45. In contrast 
with the adamantanopyrrolidine analogues, moving the 
amine nitrogen atom from position 3 to the vicinal position 
resulted in a total loss of activity in the 1,2 annulated 
adamantanopiperidine compounds 60, 62 and 63. 
Somewhat surprisingly, the antiviral activity was regained 
by shifting the nitrogen atom at position 5 thus increasing 
the distance from the 2-adamantanyl carbon. The EC50 
value of 67 was 7-fold lower (EC50 67 = 0.6 μΜ) compared 
to the structurally related piperidine 45. Also, compound 67 
was 3-fold and 14.5-fold more potent than amantadine and 
ribavirin respectively. However, methylation had a 
detrimental effect in the potency of 67. Changing the 
pyrrolidine ring in structure 19 with the isostere amino 
substituted cyclopentane ring in compound 42 enhanced 
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Table 1. Anti-influenza A virus (H3N2) activity and cytotoxicity of the 1,2-annulated adamantane heterocyclic analogues 19, 20, 
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(a) The 1,2-annulated adamantanopyrrolidines 19, 20, 21, 27 and 29, and the adamantanopiperidines 45, 47, 60, 62, 63, 67 and 69 were tested as hydrochlorides. 
Oxazolone 31, pyrazolone 33 and pyrazolothione 34 were tested as free bases. 
(b) MDCK, Madin-Darby canine kidney cells; virus strain: influenza A/Hong Kong/7/87 (H3N2). 
(c) Concentration producing 50 % inhibition of the virus-induced cytopathic effect, as determined by measuring the cell viability with the colorimetric formazan-
based MTS assay. 
(d) Minimal cytotoxic concentration, or concentration that causes microscopically detectable changes in cell morphology. 
(e) Data are shown as mean ± SD (in brackets: number of independent determinations). 
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replacement of the pyrrolidine moiety by other 5-mem-
bered heterocycles such as an isoxazolone (31), a pyrazo-
lone (33) or a pyrazolothione (34) ring led to a dramatic loss 
of activity. Furthermore, the 1,2-annulated adamantane 
dioxane (50), dioxathiane (51) and oxetane (52) showed no 
inhibitory activity at the highest concentration tested  
(~ 500 μM). Concerning the cytotoxic effects of the 
compounds, the non-substituted analogues 19, 45 and 67 
and the N-methyl substituted pyrrolidine 20 displayed very 
low cytotoxicity, with MCCs in the 439-468 μM range, thus 
resulting in remarkable selectivity indices, which varied 
from 106 for 45 to 732 for 67. It is of great interest that the 
introduction of an alkyl substituent onto the amine nitro-
gen atom of the heterocycle progressively increased the 
cytotoxicity of the compounds, leading to lower SI values. 
Finally, out of all compounds, 27 and 67 exhibited high 
activity and favorable selectivity (SI 27 200; SI 67 732). 
 No activity was observed for the γ- and δ-1,2 annu-
lated adamantane lactams against influenza A/H3N2 virus, 
in contrast with the respective pyrrolidines and piperidines. 
Surprisingly, the adamantane lactam analogues retained 
potency in the range of 1.4–30 μM when they were evalu-
ated for their antiviral activity against influenza A/Puerto 
Rico/8/34 (H1N1) strain (Table 2). Thus, lactam 15 was 
active with an EC50 value at low micromolar level. This com-
pound was 25- and 3-fold more effective than amantadine 
and ribavirin respectively and its activity was comparable 
to that of rimantadine (EC50 15 = 4.1 μΜ). N-Methyl 
substitution on the amide nitrogen atom of the parent 
compound 15 led to a 4-fold decrease in potency for the 
analogue 18 (EC50 18 = 16 μM). Therefore, N-ethyl substitu-
tion on the heterocyclic ring seems to maintain antiviral 
activity, whereas compound 16 was equipotent (EC50 16 = 
5.3 μM) to the NH congener 15 (EC50 15 = 4.1 μM).  
 
Table 2. Anti-influenza A virus (H1N1) activity and cytotoxicity of the 1,2-annulated adamantane lactams 15, 16, 18, 26, 28, 44, 
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(a) 50 % Effective concentration, or concentration causing 50 % inhibition of virus-induced cytopathic effect, as determined by measuring the cell viability with 
the colorimetric formazan-based MTS assay. 
(b) Minimum cytotoxic concentration (MCC), i.e. concentration that causes amicroscopically detectable alteration of normal cell morphology. 
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Compared with amantadine, the EC50 of the N-ethyl 
counterpart 16 was 19-fold lower, whereas it was 
equipotent to rimantadine. 
 Moving the amide nitrogen atom from position 3 to 
the vicinal position of the γ-lactam 15 yielded compound 26 
which was 7-fold less active (EC50 26 = 30 μM). The same 
trend was observed for the analogue 28; when increasing 
the distance of the amide nitrogen atom from the adaman-
tane scaffold resulted in a substantial loss of activity for the 
respective N-ethyl congener 16. Extension from a five- 
(compound 15) to a six-membered ring (compound 44)  
diminished the antiviral potency. On the other hand, shift-
ing the nitrogen atom from C-3 to the C-4 position of the 
δ-lactam 44 provided the most potent analogue 58 of this 
series with an EC50 value of 1.4 μM. Lactam 58 was 73, 4 
and 8.5 times more potent than amantadine, rimantadine 
and ribavirin, respectively. The presence of an ethyl group 
on the amide nitrogen atom of the parent compound 58 
abolished the antiviral activity for the substituted deriva-
tive 59. A further shift of the amide nitrogen atom to po-
sition 5 of the δ-lactam ring led to a 15-fold decrease in 
potency (EC50 66 = 21 μM). Replacing the lactam nitrogen 
atom of compound 15 with an oxygen atom caused a clear 
reduction in activity for the respective lactone 5. 
Molecular Dynamics Simulations 
To obtain additional insight and quantitatively explain  
the different anti-influenza virus A activity of three struc-
turally similar 1,2-annulated adamantane piperidines[64] 
MD simulations were applied.  
 MD simulations were performed on M2TM in 
complex with each Aamt ligand in POPC hydrated bilayers. 
The simulated complexes were structurally stable during 
the 200 ns simulations with no significant conformational 
changes as suggested by the RMSD of Ca carbons which 
were smaller than 2.0 Å. The ammonium groups of the 
three ligands are oriented towards the C-end with a 
progressive increased tilt from 67 to 60 and 45 (Table 3, 
Figure 5). The water molecules inside the pore form two 
separated layers forming hydrogen bonding networks. 
The adamantane is embraced by the side chains of Val27 
and the ammonium group forms two hydrogen bonds 
with the waters inside the pore (Table 3). Summarizing, 
the MD simulations suggest that 45, 60, 67 are stabilized 
inside the M2TM pore with no significant differen- 
ces between the three 1,2-annulated adamantane 
piperidines. 
Table 3. Structural and dynamic measures from 200 ns MD trajectories of M2TM-Aamt ligand complexes in POPC bilayer. 
Ligand RMSD (Cα)(a) Angle C-N vector(b) Val27-Ad(c) Ala30-Ad(c) Gly34-Ad(c) H-bonds(d) Cl-N distance(e) RMSF ligand(f) 
45 0.8 ± 0.2 39.9 ± 8.1 (C-N) 2.1 ± 0.0 1.9 ± 0.0 2.8 ± 0.1 2.0 ± 0.2 40.2 ± 8.1 0.1 
60 1.1 ± 0.2 25.7 ± 8.7 (C-N) 2.1 ± 0.0 1.9 ± 0.0 2.8 ± 0.1 1.8 ± 0.4 37.9 ± 9.2 0.1 
67 1.0 ± 0.2 16.3 ± 8.0 (C-N) 2.1 ± 0.0 1.9 ± 0.0 2.8 ± 0.1 1.8 ± 0.4 40.6 ± 7.9 0.1 
(a) Maximum root-mean-square deviation (RMSD) for Cα atoms of M2TM tetramer relative to the initial structure after root-mean-square fitting of Cα atoms of 
M2TM; in Å. 
(b) Angle between the vector along the bond from the carbon atom of the adamantane core to the ligand nitrogen atom and the normal of the membrane; in 
degrees. 
(c) Mean distance between center of mass of Val27, Ala30 or Gly34 and centers of mass of adamantane calculated using Gromacs tools; in Å. 
(d) Mean number of H-bonds between ligand's ammonium group and waters. 
(e) Mean distance in Å between the ligand N and the nearest Cl. 
(f) Maximum root-mean-square fluctuation (RMSF) for the ligand. 
 
 
      
Figure 5. (left) Superposition of the three 1,2-annulated 
adamantane piperidines bound to M2TMWT in hydrated 
POPC after 200 ns of production. (right) Snapshot from the 
simulation of 45 bound to M2TMWT in hydrated POPC after 
200 ns of production. Waters within 5 Å of the ligand define 
two layers of waters between the ligand's ammonium group 
and His37. Two hydrogen bonds between the ammonium 
group of the ligand and two water molecules of an upper 
layer close are shown. Water network that connects 
carbonyl groups in the protein (Gly34) together with van der 
Waals interactions of the adamantane core with V27 and 
A30 stabilize the ligand inside the pore with its ammonium 




 V. PARDALI et al.: 1,2-Αnnulated Adamantane Heterocyclic Derivatives … 225 
 





In summary, we have designed and synthesized a series of 
1,2-annulated aminoadamantane derivatives based on the 
structurally related M2 blockers amantadine and riman-
tadine. Fascinating standard chemistry enabled the synthesis 
of these rigid compounds with various chemical entities 
including pyrrolidines, piperidines with nitrogen atom at 
different positions of the fused ring as well as a variety of 
other heterocycles. Evaluation of their in vitro antiviral activ-
ity revealed analogues with potency against influenza A 
strains. Among the tested compounds, analogues 15, 16, 19, 
20, 21, 29, 42, 45, 47 and 58 displayed micromolar potency 
in the 1.1-7.7 μM range, while compounds 27 and 67, the 
most active against influenza A virus strain H3N2, were en-
dowed with an EC50 < 0.6 μM and were not cytotoxic. Deriv-
ative 58 exhibited EC50 value up to 2 orders of magnitude 
lower than that of amantadine and comparable to 
rimantadine against influenza A/H1N1 virus. The collected 
data obtained from the antiviral properties of this panel of 
compounds allowed a preliminary interpretation of struc-
ture-activity relationships. Substitution of the free nitrogen 
atom either in 1,2-annulated adamantanopyrrolidines and 
adamantanopiperidines or in 1,2-annulated lactams was not 
well tolerated, and in general, the activity was decreased 
with increasing the alkyl chain length. Moreover, removing 
the nitrogen atom from position 3 to the C-4 position in the 
case of 1,2-annulated pyrrolidines led to more potent ana-
logues. As concerns the 1,2-annulated adamantanopiperi-
dines, increasing the distance from the 2-adamantanyl 
carbon improved the activity observed, but only in the con-
text of shifting the amine nitrogen atom from position 3 to C-
5 position. Furthermore, the incorporation of a second het-
eroatom into the heterocycle abolished the activity, as well 
the replacement of the nitrogen atom of the lactam ring by 
an oxygen atom. The MD simulations of the three 1,2-annu-
lated adamantane piperidines define similar binding profile. 
The ammonium group participating in the formation of two 
hydrogen bonds with ordered waters inside the channel and 
the adamantane cage are located near the hydrophobic re-
gion of Val27 and Ala30. The three molecules inclined differ-
ently inside the M2TM pore in order to form hydrogen bonds 
with water molecules. Additional kinetic experiments using 
electrophysiology can account for the different potency of 
these molecules. Finally, this work provides an extended 
structure-activity relationship study, while some insight into 
the rational design of potential M2 inhibitors is gained for the 
development of antivirals with even increased activity and 
improved cytotoxic and resistance profile. In addition, biolog-
ical studies to evaluate the ability of these functionalized 
aminoadamantane scaffolds to block the M2 ion channel will 
be of great importance including the elucidation of the exact 
mechanism of action. 
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